Four years after receiving Hemgenix in a Phase 3 trial, bleeding rates and the use of replacement therapy are low for men ...

CSL Behring has shared positive four-year results from a late-stage study of its haemophilia B gene therapy Hemgenix ...

The study shows that 94% of patients eliminated factor IX prophylaxis and maintained near-normal factor IX levels through ...

CSL Behring's gene therapy Hemgenix four years post-infusion data continue to show sustained efficacy and safety in adults with haemophilia B: King of Prussia, Pennsylvania Monday ...

CSL (ASX: CSL; USOTC: CSLLY) has unveiled four-year results from its pivotal HOPE-B study, demonstrating the long-term ...

As many as 40% of Americans are obese, putting them at an increased risk for high blood pressure, diabetes, stroke, heart disease and certain cancers, according to the CDC.

CSL and uniQure's Hemgenix shows sustained efficacy in hemophilia B, reducing bleeding rates by 90% and eliminating ...

Data from the study showed that HEMGENIX continues to deliver sustained factor IX activity levels for up to four years post-treatment. The treatment also provides long-term bleed protection, ...

Sign up for Chalkbeat’s free weekly newsletter to keep up with how education is changing across the U.S. President Donald Trump’s administration told schools ...

Those interested in the iX1 and iX2 will be able to get over this, as these cars are financially below what BMW envisages for the large iX. It is likely to come under pressure over the next few ...

Histamine was identified as a pro-porphyrinogenic factor in hepatocytes. Both H1- and H2-receptor blockade were shown to decrease PP-IX levels. CCZ treatment reduced hepatic mast cell infiltration ...